BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 9, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 29, 2002
View Archived Issues
Achillion Closes $41M Round, Plans Phase III Trials This Year
Achillion Pharmaceuticals Inc. raised $41 million in a private round of financing that its CEO expects will allow it to take its lead anti-infective compound through Phase II trials and into Phase III before year’s end.
Read More
Gryphon Sciences Gets $26M For Chemical Protein Products
Read More
FDA Says It Reduced Review Times As Called For In PDUFA
Read More
Genoptix Series B Raises $17M To Push Laser Cell Technology
Read More
Other News To Note
Read More
